Overview

A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD

Status:
NOT_YET_RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
AER-01-002 is a Phase 2a study being conducted to determine if inhaled fexlamose is an effective and safe treatment for adults with moderate to severe COPD. Study will compare active drug to placebo.
Phase:
PHASE2
Details
Lead Sponsor:
Aer Therapeutics